Search Results - "Frewer, P."

A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification by Van Cutsem, E., Bang, Y.-J., Mansoor, W., Petty, R.D., Chao, Y., Cunningham, D., Ferry, D.R., Smith, N.R., Frewer, P., Ratnayake, J., Stockman, P.K., Kilgour, E., Landers, D.

“…Approximately 5%–10% of gastric cancers have a fibroblast growth factor receptor-2 (FGFR2) gene amplification. AZD4547 is a selective FGFR-1, 2, 3 tyrosine…”
Get full text

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors by Balmaña, J., Tung, N.M., Isakoff, S.J., Graña, B., Ryan, P.D., Saura, C., Lowe, E.S., Frewer, P., Winer, E., Baselga, J., Garber, J.E.

“…To establish the maximum tolerated dose, determine safety/tolerability and evaluate the pharmacokinetics and preliminary efficacy of olaparib in combination…”
Get full text

Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma by Krebs, M, Lopez, J, El-Khoueiry, A, Bang, Y-J, Postel-Vinay, S, Abidah, W, Im, S-A, Khoja, L T, Standifer, N, Jones, G N, Marco-Casanova, P, Frewer, P, Berges, A, Cheung, A, Stephens, C, Felicetti, B, Dean, E, Pierce, A, Hollingsworth, S

Get full text

The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment by Haro, J. M., Edgell, E. T., Frewer, P., Alonso, J., Jones, P. B.

“…Objective:  To describe the baseline findings and study population of the Schizophrenia Outpatient Health Outcomes (SOHO) Study. Method:  The SOHO study is an…”
Get full text

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor by Dickinson, Paul A, Cantarini, Mireille V, Collier, Jo, Frewer, Paul, Martin, Scott, Pickup, Kathryn, Ballard, Peter

“…Preclinical and clinical studies were conducted to determine the metabolism and pharmacokinetics of osimertinib and key metabolites AZ5104 and AZ7550…”
Get full text

Decision-making in early clinical drug development by Frewer, Paul, Mitchell, Pat, Watkins, Claire, Matcham, James

“…This paper illustrates an approach to setting the decision framework for a study in early clinical drug development. It shows how the criteria for a go and a…”
Get full text

TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI by Han, J.-Y., Sequist, L.V., Ahn, M.-J., Cho, B.C., Yu, H., Kim, S.-W., Yang, J.C.-H., Lee, J.S., Su, W.-C., Kowalski, D., Orlov, S., Cantarini, M., Verheijen, R.B., Mellemgaard, A., Frewer, P., Ou, X., Oxnard, G.

Get full text

413PDPhase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma by Krebs, M, Lopez, J, El-Khoueiry, A, Bang, Y-J, Postel-Vinay, S, Abidah, W, Im, S-A, Khoja, L T, Standifer, N, Jones, G N, Marco-Casanova, P, Frewer, P, Berges, A, Cheung, A, Stephens, C, Felicetti, B, Dean, E, Pierce, A, Hollingsworth, S

Get full text

A Phase I Study of AZD9291 in Patients with Egfr-Tki-Resistant Advanced Nsclc – Updated Progression Free Survival and Duration of Response Data by Jänne, P.A., Ahn, M.-J., Kim, D.-W., Kim, S.-W., Planchard, D., Ramalingam, S.S., Frewer, P., Cantarini, M., Ghiorghiu, S., Yang, J.C.-H.

Get full text

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study by Oertel, Wolfgang H., Wolters, Erik, Sampaio, Cristina, Gimenez-Roldan, Santiago, Bergamasco, Bruno, Dujardin, Max, Grosset, Donald G., Arnold, Guy, Leenders, Klaus L., Hundemer, Hans-Peter, Lledó, Alberto, Wood, Andrew, Frewer, Paul, Schwarz, Johannes

“…Dopamine agonists are used as initial treatment in patients with Parkinson's disease (PD) to reduce incidence and severity of motor complications. This…”
Get full text

454PPRE-CLINICAL AND CLINICAL EVALUATION OF AZD9291, A MUTATION-SPECIFIC INHIBITOR, IN TREATMENT-NAïVE EGFR MUTATED NSCLC by Ramalingam, S.S., Ohe, Y., Nogami, N., Yang, J.C., Eberlein, C., Ashton, S., Mellor, M., Spitzler, P., Meador, C., Ichihara, E., Cross, D., Pao, W., Ballard, P., Hughes, G., Cantarini, M., Frewer, P., Ghiorghiu, S., Janne, P.A.

“…Abstract Aim: AZD9291 is an oral, irreversible EGFR-TKI effective against EGFR-TKI-sensitising (EGFRm+) and resistance T790M mutations. It is efficacious in…”
Get full text

449PDUPDATED SAFETY AND EFFICACY FROM A PHASE I STUDY OF AZD9291 IN PATIENTS (PTS) WITH EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER (NSCLC) by Yang, J.C., Kim, D., Planchard, D., Ohe, Y., Ramalingam, S.S., Ahn, M., Kim, S., Su, W., Horn, L., Haggstrom, D., Felip, E., Kim, J., Frewer, P., Cantarini, M., Ghiorghiu, S., Ranson, M., Janne, P.A.

“…Abstract Aim: AZD9291 is a potent, selective, irreversible EGFR-TKI, effective against the EGFR-TKI-sensitising (EGFRm+) and resistance T790M mutations. Here…”
Get full text

Pre-Clinical and Clinical Evaluation of Azd9291, a Mutation-Specific Inhibitor, in Treatment-Naïve Egfr Mutated Nsclc by Ramalingam, S.S., Ohe, Y., Nogami, N., Yang, J.C., Eberlein, C., Ashton, S., Mellor, M., Spitzler, P., Meador, C., Ichihara, E., Cross, D., Pao, W., Ballard, P., Hughes, G., Cantarini, M., Frewer, P., Ghiorghiu, S., Janne, P.A.

Get full text

Updated Safety and Efficacy from a Phase I Study of Azd9291 in Patients (Pts) with Egfr-Tki-Resistant Non-Small Cell Lung Cancer (Nsclc) by Yang, J.C., Kim, D., Planchard, D., Ohe, Y., Ramalingam, S.S., Ahn, M., Kim, S., Su, W., Horn, L., Haggstrom, D., Felip, E., Kim, J., Frewer, P., Cantarini, M., Ghiorghiu, S., Ranson, M., Janne, P.A.

Get full text

Clinical and functional status over the first three months of treatment: Results from the schizophrenia outpatient health outcomes (SOHO) study by Edgell, E.T., Haro, J.M., Frewer, P., Wright, P.

Get full text

P.2.143 Extrapyramidal symptoms after six months of treatment: Results from the schizophrenia outpatient health outcomes (SOHO) study by Wright, P., Haro, J.M., Frewer, P., Novick, D., Edgell, E.T.

Get full text

Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: A comparison of two dosage algorithms by KEHELY, Anne, BATES, Peter C, MAREK, Josef, RUSSELL-JONES, David, SONKSEN, Peter, ATTANASIO, Andrea F, FREWER, Paul, BIRKETT, Martin, BLUM, Werner F, MAMESSIER, Pascale, EZZAT, Shereen, HO, Ken K. Y, LOMBARDI, Gaetano, LUGER, Anton

“…The aim of GH replacement therapy in GH-deficient adults is to optimize response with minimum incidence of adverse reactions, but optimal therapy regimens are…”
Get full text

Confirmation of severe GH deficiency after final height in patients diagnosed as GH deficient during childhood by Attanasio, Andrea F., Howell, Simon, Bates, Peter C., Blum, Werner F., Frewer, Paul, Quigley, Charmian, Shalet, Stephen M.

“…Summary objective Human GH treatment of patients with childhood‐onset (CO) growth hormone deficiency (GHD) ceases when they reach final height; this provides…”
Get full text

The treatment of schizophrenia across Europe: Between country baseline differences in the schizophrenia outpatient health outcomes (SOHO) study by Edgell, E.T., Haro, J.M., Frewer, P., Wright, P., Novick, D.

Get full text

Gender differences in schizophrenia: Results from the schizophrenia outpatient health outcomes study (SOHO) by Haro, J.M., Gasquet, I., Le´pine, J.P., Edgell, E.T., Frewer, P., Novick, D., Usall, J.

Get full text